Kamada Corp - Utang jangka cendhak marang modal KMDA

Kamada Ltd. (KMDA) develops drugs for rare pathologies, leveraging demand that remains independent of economic cycles and seasonality. Market fluctuations in the share price demonstrate the 0.00 metric, while stringent FDA requirements and patents block new competitors from entering the market. High management stability and expansion in the US provide the company with strong support from the investment community.

This indicator measures the proportion of short-term liabilities relative to the company's equity. Analyzing this ratio allows for an assessment of liquidity risk in the event of a sharp credit market contraction. The trend of the short-term debt-to-equity ratio reflects the degree of the company's dependence on operational refinancing. For Kamada Ltd. (KMDA), this metric confirms financial stability during its expansion into the US market.